Acute Kidney Injury
Welcome,         Profile    Billing    Logout  
 76 Companies   48 Products   48 Products   54 Mechanisms of Action   699 Trials   45626 News 


12345678910111213...817818»
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Journal:  Transient inhibition of sodium-glucose cotransporter 2 after ischemia/reperfusion injury ameliorates chronic kidney disease. (Pubmed Central) -  Mar 26, 2024   
    Sodium-glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin (Dapa), exhibited nephroprotective effects in patients with chronic kidney disease (CKD)...This was evidenced by improvements in proteinuria, CrCl, glomerulosclerosis, and fibrosis. Our findings underscore the potential of Dapa in preventing maladaptive repair following AKI, emphasizing the crucial role of early intervention in mitigating AKI long-term consequences.
  • ||||||||||  Review, Journal:  Cardiopulmonary bypass associated acute kidney injury: better understanding and better prevention. (Pubmed Central) -  Mar 26, 2024   
    Based on recent research, we discuss the potential pathogenesis of AKI that may result from CPB, including compromised perfusion and oxygenation, inflammatory activation, oxidative stress, coagulopathy, hemolysis, and endothelial damage. Finally, we explore current interventions aimed at preventing and attenuating renal impairment related to CPB, and presenting these measures from three perspectives: (1) avoiding CPB to eliminate the fundamental impact on renal function; (2) optimizing CPB by adjusting equipment parameters, optimizing surgical procedures, or using improved materials to mitigate kidney damage; (3) employing pharmacological or interventional measures targeting pathogenic factors.
  • ||||||||||  Review, Journal:  Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials. (Pubmed Central) -  Mar 26, 2024   
    We discuss lessons learned and potential opportunities to improve the design of clinical trials and generate actionable evidence in future research. We specifically discuss the role of enrichment strategies to target populations that are most likely to derive benefit and the importance of patient-centered clinical trial endpoints and appropriate trial designs with the aim to provide guidance in designing future trials.
  • ||||||||||  Journal:  Iatrogenic hyperchloremia: An overview in hospitalized patients for pharmacists. (Pubmed Central) -  Mar 26, 2024   
    Management of hyperchloremia is preventative in nature and can be mitigated through management of resuscitation fluids, medication diluents, and total parenteral nutrition. Inpatient pharmacists should be aware of the potential risk of fluid-associated hyperchloremia and assist with optimal fluid management to prevent and manage hyperchloremia.
  • ||||||||||  Journal:  Acute kidney injury in children with lymphoma. (Pubmed Central) -  Mar 26, 2024   
    TLS, lung infection, and lymphoma clinical stage were identified as independent risk factors for AKI in children with lymphoma during the first 30 days of hospitalization. Clinicians should increase their awareness of AKI in hospitalized patients with lymphoma.
  • ||||||||||  Journal:  Role of Interleukin 1 Receptor 2 in Kidney Disease. (Pubmed Central) -  Mar 25, 2024   
    Chronic kidney disease, acute kidney injury, lupus nephritis, IgA nephropathy, renal clear cell carcinoma, rhabdoid tumor of kidney, kidney transplantation, and kidney infection were all shown to have abnormal IL-1R2 expression. IL-1R2 may be a potential marker and a promising therapeutic target for kidney disease.
  • ||||||||||  Journal:  Pyxinol Fatty Acid Ester Derivatives J16 against AKI by Selectively Promoting M1 Transition to M2c Macrophages. (Pubmed Central) -  Mar 25, 2024   
    Based on this, PJ16 was validated in the animal model of unilateral ureteral obstruction, which showed that it improves renal function and inhibits renal tissue fibrosis by decreasing inflammatory responses, reducing macrophage inflammatory infiltration, and preferentially upregulating M2c macrophages. In conclusion, our study is the first to show that PJ16 resists AKI and fibrosis by mechanistically regulating macrophage function by modulating the phenotypic transition from M1 to M2 macrophages, mainly M2c macrophages.
  • ||||||||||  Review, Journal:  Review article: Recent advances in ascites and acute kidney injury management in cirrhosis. (Pubmed Central) -  Mar 25, 2024   
    New treatment strategies emerged from better understanding of the pathophysiology of ascites and HRS-AKI have shown improved prognosis in these patients. The future will see many of these approaches confirmed in large multi-centre clinical trials with the aim to benefit the patients with ascites and HRS-AKI.
  • ||||||||||  Retrospective data, Journal:  Acute kidney injury in hospitalized children with proteinuria: A multicenter retrospective analysis. (Pubmed Central) -  Mar 25, 2024   
    NEUT% may provide physicians with more information about disease development and prognosis. Children with proteinuria on the first day of hospital care services may have an increased odds of higher severity AKI, need for renal replacement therapy, shock and/or antibiotic use, and all-cause mortality at 30 days post-admission, with no significant association found for critical care services, mechanical intubation, or inotrope or vasopressor use.
  • ||||||||||  Journal:  SGLT2 inhibition, high-density lipoprotein, and kidney function: a mendelian randomization study. (Pubmed Central) -  Mar 25, 2024   
    The findings demonstrate that the protective effect of SGLT2 inhibition on renal function is mostly mediated by HDL particle concentrations in circulating metabolites. These results offer significant theoretical support for both the preservation of renal function and a better comprehension of the mechanisms underlying SGLT2 inhibition.
  • ||||||||||  Review, Journal:  Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition. (Pubmed Central) -  Mar 25, 2024   
    In this review, we introduce the three main metabolic pathways of AA and discuss the molecular mechanisms by which these pathways affect the progression of acute kidney injury (AKI), diabetic nephropathy (DN) and renal cell carcinoma (RCC). This review may provide new therapeutic targets for the identification of AKI to CKD continuum.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Review, Journal:  Management of pediatric hemolytic uremic syndrome. (Pubmed Central) -  Mar 25, 2024   
    Eculizumab has brought about dramatic improvements in the treatment of aHUS...Because of the rarity of aHUS, data from multiple patient registries are very important. The present report aimed to summarize the most important aspects of diagnosing and treating aHUS based on the Turkish national registry and the literature so as to improve clinical practice.
  • ||||||||||  Review, Journal:  Cellular senescence in acute kidney injury: Target and opportunity. (Pubmed Central) -  Mar 25, 2024   
    These studies have taken senescence-related research to a new level. Overall, this article comprehensively summarizes the studies on cellular senescence in AKI, aiming is to elucidate the relationship between cellular senescence and AKI, and explore treatment strategies to improve the prognosis of AKI.
  • ||||||||||  Journal:  Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury. (Pubmed Central) -  Mar 25, 2024   
    In both models, CHIP was associated with more severe AKI, greater renal proinflammatory macrophage infiltration and greater post-AKI kidney fibrosis. In summary, this work establishes CHIP as a genetic mechanism conferring impaired kidney function recovery after AKI via an aberrant inflammatory response mediated by renal macrophages.